CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 2.17 and has seen 1,728,532 shares traded in the last trading session. The company, currently valued at $9.16 Billion, closed the last trade at $129.58 per share which meant it gained $2.66 on the day or 2.1% during that session. The CRSP stock price is -3.8% off its 52-week high price of $134.5 and 75.07% above the 52-week low of $32.3. If we look at the company’s 10-day average daily trading volume, we find that it stood at 883.38 Million shares traded. The 3-month trading volume is 941.74 Million shares.
The consensus among analysts is that CRISPR Therapeutics AG (CRSP) is an Overweight stock at the moment, with a recommendation rating of 2.2. 2 analysts rate the stock as a Sell, while 1 rate it as Overweight. 5 out of 19 have rated it as a Hold, with 11 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$1.27.
Sporting 2.1% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Dec 01 when the CRSP stock price touched $134.5 or saw a rise of 3.66%. Year-to-date, CRISPR Therapeutics AG shares have moved 112.76%, while the 5-day performance has seen it change 17.8%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed 41.12%. Short interest in the company has seen 4.69 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $102.63, which means that the shares’ value could jump -20.8% from current levels. The projected low price target is $45 while the price target rests at a high of $140. In that case, then, we find that the current price level is +8.04% off the targeted high while a plunge would see the stock lose -65.27% from current levels.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Figures show that CRISPR Therapeutics AG shares have underperformed across the wider relevant industry. The company’s shares have gained +99.51% over the past 6 months, with this year growth rate of -524.79%, compared to 14.2% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -349% and -16.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be -99.1%.
14 analysts offering their estimates for the company have set an average revenue estimate of $2.5 Million for the current quarter. 9 have an estimated revenue figure of $1.82 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $77.02 Million and $3.04 Million respectively for this quarter and the next, and analysts expect sales will grow by -96.8% for the current quarter and -40.1% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +54% over the past 5 years. Earnings growth for 2020 is a modest +134.1%.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 13.8% of the company shares, while shares held by institutions stand at 69.33% with a share float percentage of 80.43%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 404 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 8.46 Million shares worth more than $707.37 Million. As of September 29, 2020, ARK Investment Management, LLC held 11.97% of shares outstanding.
The other major institutional holder is Capital International Investors, with the holding of over 7.39 Million shares as of September 29, 2020. The firm’s total holdings are worth over $618.46 Million and represent 10.47% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. As of July 30, 2020, the former fund manager holds about 5.79% shares in the company for having 4091443 shares of worth $349.65 Million while later fund manager owns 3.22 Million shares of worth $269.18 Million as of September 29, 2020, which makes it owner of about 4.56% of company’s outstanding stock.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.